BIOCHEMICAL PARAMETERS OF THE LIVER UNDER THE PRESENCE OF ANTI-SARS-CoV-2 IgG IN THE BLOODSTREAM
DOI 10.17721/1728.2748.2022.88.33-40
Keywords:
SARS-CoV-2, biochemical parameters of the liver, inflammationAbstract
COVID-19 is a systemic disease caused by infection SARS-CoV-2, which affects the respiratory organs in the initial stages, but it threats for healthy even in suffered patients due to unpredictability complications. There is enough the clinical information about liver tissue dysfunction in patients with COVID-19. The imbalance of the necessary biochemical parameters of the liver as called the main organ ensuring the process and regulation of metabolism can cause the complications in the body during COVID-19. Our study is aimed to the analysis of key biochemical parameters of liver tissue in donors who has suffered COVID-19 and there are anti-SARS-CoV-2 IgG titers in bloodstream. We have found that the biochemical parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatase and bilirubin might change depending on the titer of anti-SARS-CoV-2 IgG, compared with donor group without anti-SARS-CoV-2 IgG. Such processes could be the cause of post-COVID-19 complications, so early diagnostis of changes in the liver tissue function must help to prevent or to stop critical consequences. Moreover, the potential effect of acute inflammatory process, which was observed in COVID-19, on changes in the liver biochemical parameters was analyzed. We have found the positive correlation between activity ALT and ferritin / C-reactive protein as biomarkers of the acute inflammatory phase. This study could help to improve knowledge about the mechanisms of dependence of biochemical processes in the liver tissues on the process of COVID-19 disease, which might be useful for developing new approaches to the diagnostis and treatment of post-COVID-19 syndrome.
References
Vitiello A., La Porta R., D'Aiuto V., Ferrara F. The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver J. 2021; 11(1):11. doi: 10.1186/s43066-021-00082-y.
Wang X., Lei J., Li Z., Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne). 2021; 8(2). doi: 10.3389/fmed.2021.651658.
McConnell M. J., Kondo R., Kawaguchi N., Iwakiri Y. Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatol Commun. 2022; 6(2):255-269. doi: 10.1002/hep4.1843.
Sonzogni A., Previtali G., Seghezzi M., Grazia Alessio M., Gianatti A., Licini L., Morotti D., Zerbi P., Carsana L., Rossi R., Lauri E., Pellegrinelli A., Nebuloni M. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020; 40(9):2110-2116. doi: 10.1111/liv.14601.
Rapkiewicz A. V., Mai X., Carsons S. E., Pittaluga S., Kleiner D. E., Berger J. S., Thomas S., Adler N. M., Charytan D. M., Gasmi B., Hochman J. S., Reynolds H. R. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine. 2020; 24: 1-9. doi: 10.1016/j.eclinm.2020.100434.
Lagana S., Kudose S., Iuga C et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol 2020; 33: 2147–2155. https://doi.org/10.1038/s41379-020-00649-x
Kopec A. K., Abrahams S. R., Thornton S., Palumbo J. S., Mullins E. S., Divanovic S., Weiler H., Owens A. P. 3rd, Mackman N., Goss A., van Ryn J., Luyendyk J. P., Flick M. J. Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest. 2017; 127(8):3152-3166. doi: 10.1172/JCI92744.
Herrero R., Sаnchez G., Asensio I., Lоpez E., Ferruelo A., Vaquero J., Moreno L., de Lorenzo A., Bañares R., Lorente J. A. Liver-lung interactions in acute respiratory distress syndrome. Intensive Care Med Exp. 2020; 18 (48): 1-13. doi: 10.1186/s40635-020-00337-9.
Gibson P. G., Qin L., Puah S. H. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS. Med J 2020; 213(2):54-56. doi: 10.5694/mja2.50674.
Vitiello A., Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci. 2020; 262(8): 23-34. doi: 10.1016/j.lfs.2020.118510.
Zbirnyk metodychnykh rekomendatsii z vykorystannia test-naboriv firmy vyrobnyka "Human". – Rezhym dostupu : http://www.human.de/en/productNew/Clinical_Chemistry/Reagents_and_Consumables/Multipurpose_Reagents.php.
Shaw L. M., Strømme J. H., London J. L., Theodorsen L. IFCC methods for the measurement of catalytic concentration of enzymes. Part 4. IFCC method for gamma-glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gamma-glutamyltransferase, EC2.3.2.2]. J Clin Chem Clin Biochem. 1983 Oct; 21(10):633-46. PMID: 6139407.
Tolman K. G. and R. Rej. (1999) Liver function. In: Burtis CA, Ashwood ER, editors. Tietz textbook of clinical chemistry. 3rd ed. Philadelphia (PA): Saunders; 1136-1137.
Dipalo, Mariella, Gnocchi, Cecilia, Aloe, Rosalia and Lippi, Giuseppe. "Comparison of the novel Maglumi ferritin immunoluminometric assay with Beckman Coulter DxI 800 ferritin" LaboratoriumsMedizin, vol. 40, no. 3, 2016, pp. 221-223.doi: 10.1515/labmed-2016-0003.
Mohit E., Rostami Z., Vahidi H. A comparative review of immunoassays for COVID-19 detection. Expert Rev Clin Immunol. 2021 Jun; 17(6):573-599. doi: 10.1080/1744666X.2021.1908886.
Chau T. N., Lee K. C., Yao H., Tsang T. Y., Chow T. C., Yeung Y. C., Choi K. W., Tso Y. K., Lau T., Lai S. T., Lai C. L. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004; 39(2):302-10. doi: 10.1002/hep.20111.
Chai X., Hu L., Zhang Y., Han W., Lu Z., Ke A. et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020; 2(3): 1-13. doi: 0.1101/2020.02.03.931766
Zhang C., Shi L., Wang F. S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1.
Saini R. K., Saini N., Ram S., Soni S. L., Suri V., Malhotra P., Kaur J., Verma I., Sharma S., Zohmangaihi D. COVID-19 associated variations in liver function parameters: a retrospective study. Postgrad Med J. 2022; 98(1156):91-97. doi: 10.1136/postgradmedj-2020-138930.
Еaneva G., Dimitrov D., Velikova T. Liver dysfunction as a cytokine storm manifestation and prognostic factor for severe COVID-19. World J Hepatol. 2021; 13(12):2005-2012. doi: 10.4254/wjh.v13.i12.2005.
Ali K. M., Ali A. M., Tawfeeq H. M., Figueredo G. P., Rostam H. M. Hypoalbuminemia in patients following their recovery from severe coronavirus disease 2019. J Med Virol. 2021; 93(7):4532-4536. doi: 10.1002/jmv.27002.
